Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Summary

This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such as lenalidomide, use substances made from living organisms that may kill cancer cells by blocking blood flow to the cancer and by stimulating white blood cells to kill the cancer cells.

Timeline

Start

2014-11-13

Primary completion

2021-11-30

Completion

2021-11-30

Drugs

Indications